Cannabis & Wellness

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

In a landmark collaboration, ink giant INX is deploying an AI operating system to accelerate innovation, potentially cutting R&D time from months to days.

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

A $20M round for CELYSTRA Pharma isn't just a launch; it's a strategic maneuver to solve Canada's rare disease gap and redefine Québec's role in the market.

A geo-targeting firm captured data from 1M cannabis consumers' phones to create a compliant ad audience. It's a strategic masterstroke, but it opens a new front in the battle over data privacy.

A major U.S. fund's increased stake in KT&G signals deep trust in its global expansion, backed by record Q1 growth and a promise of richer dividends.

A deadly, vaccine-less Ebola strain is spreading in Central Africa. As governments scramble, the CDC Foundation deploys its most potent weapon: agile funding.

As Capricor presents its late-stage DMD drug and novel exosome platform, can it convince investors it has the key to both patient impact and market success?

An aging world and failing antibiotics are driving a surge in pneumonia. Now, a new generation of therapies is being built to fight back. Here's how.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

A CPG veteran launches Lioness, a functional gummy snack for women. Can timed ingredients and a massive retail launch redefine the wellness market?

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

Wilson Elser’s 2026 Chambers rankings reveal more than legal wins; they map a strategy of mastering niche markets from cannabis law to NTSB disasters.

VFF's balance sheet didn't need the cash, so why take it? A deep dive into a strategic capital raise that's less about liquidity and more about legitimacy.

A family-owned hemp company's recent award from Beer Connoisseur is no fluke. It’s a key signal of the booming, multi-billion-dollar THC beverage market.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.